BioCentury
ARTICLE | Clinical News

ReoPro data

November 7, 1994 8:00 AM UTC

The Malvern, Penn., company said that its 103-patient PROLOG trial achieved its goal of reducing major bleeding events in the treatment group to the 3.3 percent level seen in the placebo group of its previous pivotal EPIC trial.

Angioplasty patients received a bolus plus infusion of ReoPro with either standard weight-adjusted or low-dose weight-adjusted heparin. Heparin doses in the EPIC trial weren't adjusted by weight. ...